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Triple-negative breast carcinoma is a group of breast cancers that is known for aggressive 
and unpredictable clinical behavior affecting also younger women. In 
immunohistochemical staining, triple-negative breast carcinoma is negative for estrogen- 
and progesterone receptors, proliferation marker Ki-67 and growth factor receptor HER2. 
Prognostic clinical factors usually used in evaluating the prognosis of breast cancer, such 
as spreading to lymph nodes, are not optimal in predicting the outcome in triple-negative 
cancer. 
Immune response in malignancy has been widely studied in recent years in hope for new 
targeted therapies and even understanding the mechanisms underlying the formation of 
neoplasms.  Regarding triple-negative breast cancer, the results have been divergent and 
scarce. However, it seems that this subgroup of breast cancers has even distinct immune 
microenvironment compared to other breast cancer types. The purpose of this study was 
to survey immunological microenvironment in triple-negative breast cancer by detecting 
a wide range of different immune cells and figuring out if they have any influence on the 
prognosis.  
The material comprises of tissue samples collected during 2000-2015 in Turku University 
Hospital and follow-up data provided by Auria Biobank. Tissues were stained 
immunohistochemically in microarrays to detect immune cells and determine the activity 
of immune response. Part of the samples were evaluated with an automated analyzing 
tool ImmunoRatio. The tool did not detect some of the staining patterns, and those were 
evaluated by hand by an experienced pathologist.  
The amount of stromal tumor infiltrating lymphocytes (TILs) and frequency of CD8+ T 
cells in the periphery of the tumor were both independent risk factories in this study. Each 
10% increment in stromal TIL indicated 20% reduced risk of death. Other studied 
immune cells; B cells, macrophages and CD4+ T cells, were not significant prognostic 
factors in this study. 
Based on this study, CD8+ T cells and stromal lymphocytes could be promising tools to 
improve prediction of the prognosis of triple-negative breast cancer patients. It would be 
a great help in clinical work to be able to identify those patients with aggressive and 
relapse prone disease, so the heavy and expensive treatments can be targeted. 
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Abstract
Purpose Tumor inflammatory response was evaluated as a prognostic feature in triple-negative breast cancer (TNBC) and 
compared with the clinical prognosticators of breast cancer and selected biomarkers of cancer cell proliferation.
Methods TNBC patients (n = 179) with complete clinical data and up to 18-year follow-up were obtained from Auria 
biobank, Turku University Hospital, Turku, Finland. Tumor-infiltrating lymphocytes (TILs) and several subtypes of inflam-
matory cells detected with immunohistochemistry were evaluated in different tumor compartments in full tissue sections 
and tissue microarrays.
Results Deficiency of stromal TILs and low number of  CD8+ T cells independently predicted mortality in TNBC (HR 2.4, 
p 0.02 and HR 2.1, p 0.02, respectively). Each 10% decrease in stromal TILs resulted in 20% increased risk of mortality. An 
average of 13.2-year survival difference was observed between the majority (> 75%) of patients with low (< 14% of TILs) 
vs high (≥ 14% of TILs) frequency of  CD8+ T cells. The prognostic value of TILs and  CD8+ T cells varied when evaluated 
in different tumor compartments. TILs and  CD8+ T cells were significantly associated with Securin and Separase, essential 
regulators of metaphase–anaphase transition of the cell cycle.
Discussion TILs and  CD8+ T cells provide additional prognostic value to the established clinical prognostic markers in 
TNBC. However, possible clinical applications would still benefit from systematic guidelines for evaluating tumor inflam-
matory response. Increasing understanding on the interactions between the regulation of cancer cell proliferation and inflam-
matory response may in future advance treatment of TNBC.
Keywords TNBC · Inflammation · Proliferation · TIL · CD8 · Prognosis
Introduction
Tumor microenvironment—the combination of neoplastic, 
inflammatory and pro-tumoral stromal cells and their asso-
ciated soluble factors—conducts cellular interactions with 
crucial roles in malignancy (Monnot and Romero 2018). Of 
particular interest is the inflammatory cell component which, 
depending on the immunogeneity of the neoplasm, may be 
involved in complicated tumor-promoting or -suppressing 
mechanisms. Among these, inflammatory cells may either 
suppress tumor growth through destruction of malignant 
cells or, conversely, establish an immunosuppressive micro-
environment which favors escape of the tumor cells from 
the anti-tumoral immune response (da Silva et al. 2019). 
Tumor microenvironment is also known to enhance tumor 
progression by recruiting stromal cells to provide growth 
signals stimulating cell proliferation and metastatic capacity. 
Understanding the crosstalk between immune response and 
proliferative activity may provide potential new prognostic 
and predictive markers for cancer (Yuan et al. 2016).
Reflecting the versatile involvement of immune response 
in malignancy, inflammatory cells have been reported with 
numerous and partly discrepant roles in different types of 
tumors. Recently, specific subtypes of inflammatory cells 
and their impact on disease survival and treatment response 
have been described in different subtypes of breast cancer 
(Yang et al. 2018). Among these, triple-negative breast 
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carcinoma (TNBC) and, particularly its so-called immu-
nomodulatory subtype, have been reported with immuno-
genic properties distinct from other breast carcinomas (Mat-
sumoto et al. 2015; Lehmann et al. 2011).
TNBC commonly affects younger women, and is known 
for particularly aggressive clinical behavior and sinis-
ter outcome (Bianchini et al. 2016). For long, TNBC has 
comprised a specific treatment challenge due to lack of 
targeted therapeutic options. Recently, however, immune 
checkpoint-based therapies exploiting the immune/tumor 
interaction have provided for PD-L1+ metastatic or locally 
advanced TNBC significant survival benefit (Schmid et al. 
2018). There are hopes that gaining more understanding on 
tumor-infiltrating lymphocytes (TILs) and the prevalence of 
the TIL subpopulations might reveal novel biomarkers for 
TNBC. Also, the interrelation between cell proliferation and 
tumor microenvironment has been suggested with prognostic 
and predictive potential in cancer (Haschka et al. 2018). Par-
ticularly, abnormal proliferation resulting in chromosomal 
instability (CIN) and aneuploid DNA content—common 
features of TNBC—have been observed in association with 
upregulated expression of genes mediating immune response 
based on stimulation of pro-inflammatory signals (Santa-
guida et al. 2017).
In this study, specific features of inflammatory response 
are characterized in TNBC. The study is based on a total of 
179 patients with complete clinical data and up to 18-year 
follow-up. Among the studied markers of inflammatory 
response and the established clinicopathological risk fac-
tors of breast cancer, only TILs and  CD8+ cytotoxic T cells 
were significantly associated with disease-specific survival 
in TNBC. Previous literature has suggested that overexpes-
sion of the metaphase–anaphase regulators Securin and 
Separase promote cell proliferation and CIN in cancer and 
predict significantly increased breast cancer mortality (Nas-
myth 2002; Gurvits et al. 2017). In the present findings, we 
also observed an association between increased immunoex-
pression of Securin and Separase and decreased prevalence 
of TILs and  CD8+ T cells supporting previous hypotheses 
that dysfunctional cell proliferation may be interrelated to 
inflammatory reaction in TNBC.
Materials and methods
Patients
The study comprises 179 women diagnosed with unilateral 
TNBC in Turku University Hospital, Turku, Finland, dur-
ing 2000–2015 (Table 1). The cases were included in the 
material based on WHO criteria (Lakhani et al. 2012) and 
St. Gallen consensus guidelines for surrogate markers of 
molecular subclassification (Coates et al. 2015). All patients 
were surgically treated with resection or mastectomy. Fol-
lowing resection, the patients were submitted for radiation 
therapy. The use of cytostatic drugs was based on interna-
tional guidelines for treatment of TNBC at the time of diag-
nosis (Goldhirsch et al. 2009). None of the patients received 
neoadjuvant treatment. Complete clinical and follow-up data 
were collected from patient files available through Auria 
biobank, Turku University Hospital, Turku, Finland (http://
www.auria bioba nk.fi). Causes of death were obtained from 
autopsy reports, death certificates and from Finnish Can-
cer Registry (http://www.cance r.fi) resulting in maximum 
follow-up period of 18 years (mean 8 years).
Tissues
Formalin-fixed (pH 7.0) and paraffin-embedded archival 
tumor tissue of each patient was available through Auria 
biobank. The most representative tumor block of each 
patient was selected by experienced breast pathologists (HR 
and PK) and was available for the study as full tumor section 
and in tissue microarray (TMA). The full sections allowed 
evaluation of the central and peripheral areas of the tumors, 
as well as non-tumorous tissue outside the tumor borders. 
The TMAs comprised two tissue cores of each tumor, one 
from the central and another from the peripheral area. The 
TMAs were prepared by first identifying representative 
tumor areas on scanned images of HE-stained sections (3D 
HISTOTECH, Budapest, Hungary), then punching 1.5-mm-
diameter cylinders from the blocks and, finally, constructing 
the tissue cores into TMAs using an automated tissue arrayer 
(TMA Grand Master machine, 3D HISTOTECH, Budapest, 
Hungary).
Immunohistochemistry (IHC)
Inflammatory cells expressing CD8, CD20 and CD68 were 
detected by immunohistochemistry using BenchMark XT 
immunostainer and CD163, FoxP3 and MAC387 clone to 
recognize S100A8/9/12 complex expressed by macrophages 
and monocytes using Discovery XT (Roche Diagnostics/
Ventana Medical Systems, Tucson, AZ, USA) following 
the standard immunohistochemical staining procedures of a 
pathology laboratory (Table 2). Securin and Separase were 
Table 1  Summary of the clinical features of the patients (n = 179)
Mean age at diagnosis (range) (years) 60 (27–92)
Axillary lymph node metastasis (%) 33
Mean tumor size (range) (cm) 2.5 (0.5–8.5)
Basal differentiation (%) 83
Mean Ki-67 (range) (%) 50.2 (2–90)
Breast cancer deaths (%) 29
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detected using Labvision Autostainer (Thermo-Fisher Sci-
entific, Fremont, CA, USA) as described earlier (Gurvits 
et al. 2017). Expressions for estrogen (ER) and progesterone 
receptors (PR), as well as HER2 amplification, were ruled 
out using standard IHC practice and, in case of Her2-immu-
nopositivity scores 2+ and 3+, by negative HER2 amplifi-
cation status in double in situ hybridizations with chromo-
some 17 probe (Wolff et al. 2014; Goldhirsch et al. 2013). 
Expressions for epidermal growth factor receptor (EGFR) 
and cytokeratins 5 and 6 (CK5/6) were detected according to 
standard IHC practice and used to indicate basal differentia-
tion (Lakhani et al. 2012).
Evaluation of tumor‑infiltrating lymphocytes (TILs)
Morphological evaluation of TILs was performed by an 
experienced breast pathologist (PK) in digitalized images 
of full tissue sections (4 µm, magnification 400×) compris-
ing the whole tumor or at least a representative 15-mm-
diameter area of the infiltrative tumor. The inflammatory 
response was defined as infiltration of mononuclear cells, 
excluding polymorphonuclear leukocytes from the analy-
ses. All evaluations were performed avoiding areas with 
necrosis, suboptimal preservation, previous biopsy site 
and technical artifacts. The evaluations were performed 
following the international consensus recommendations 
(Salgado et al. 2015; Hendry et al. 2017; https ://www.
tilsi nbrea stcan cer.org/) and the known biologically and 
clinically relevant morphological patterns of inflammatory 
infiltrates in breast cancer (Salgado et al. 2015).
To begin with the evaluations, the extent of TILs was 
registered as the area fraction (%) of the total stromal com-
ponent of the tumor (so-called stromal TIL). In addition 
to evaluating the whole tumor area, stromal TILs were 
evaluated separately in the central area and in the periph-
eral invasive front of the tumors. Next, the extent of TILs 
was evaluated in the malignant epithelial compartment by 
registering the inflammatory cells in cell-to-cell contact 
with cancer cells and determining their number in relation 
(%) to cancer cells as the average from 3 sets of 100 cancer 
cells (so-called intratumoral TIL). Also these evaluations 
were repeated independently in the whole tumor as well as 
in the central area and in the invasive front of the tumors. 
Finally, outside the tumor in the adjacent normal tissue, 
the existence of tertiary lymphoid structures (TLS) was 
registered. TLSs were defined as a lymphocyte aggregates 
with a distinguishable T-cell zone and a B-cell follicle and 
registered as present vs absent.
Immunohistochemical evaluation of inflammatory 
response
Immunohistochemical evaluations were performed on 
the TMAs by quantifying the fraction of immunopositive 
inflammatory cells separately in tissue cores represent-
ing the central and peripheral areas of each tumor. IHC 
for CD8 and CD20 was evaluated using the automated 
image analysis software ImmunoRatio (HV) (version 
1.0c) for ImageJ (version 1.51s) (Institute of Biomedical 
Technology, University of Tampere, Tampere, Finland) 
(Tuominen et al. 2010). To ensure concordance of evalua-
tions throughout the material, the thresholds for register-
ing immunopositivity were determined based on visual 
observation without using blank field correction and the 
initially set thresholds were applied throughout the mate-
rial. IHC for CD68, CD163, FoxP3 and MAC387 clone 
was evaluated subjectively (PK). The fraction (%) of CD68 
immunopositive cells was calculated in separate repre-
sentative tumor foci in relation to sets of 100 cancer cells 
(minimum one and maximum three foci) and the aver-
age value of the foci was registered for each tissue core. 
Due to their diffuse staining patterns, CD163, FoxP3 and 
MAC387 clones were classified into negative vs positive 
subgroups. Immunoevaluations for Securin and Separase 
were performed as previously described (Gurvits et al. 
2016, 2017). Tissue cores with suboptimal tissue preser-
vation or less than 100 cancer cells were excluded from 
the analysis.
Table 2  Summary of used antibodies
Origin Clone Source Dilution
CD8 Rabbit SP57 Roche Diagnostics/
Ventana
RTU 
CD20 Mouse L26 Roche Diagnostics/
Ventana
RTU 
CD68 Mouse PG-M1 Dako 1:100
CD163 Rabbit K20-T Novus Biologicals 1:50
FoxP3 Mouse 236A/E7 Abcam 1:100
S100A8/A9 Mouse MAC387 Novus Biologicals 1:50
Securin Mouse DCS-280 Novus Biologicals 1:100
Separase Mouse 6H6 Abnova 1:1000
ER Rabbit SP1 Roche Diagnostics/
Ventana
RTU 
PR Rabbit 1E2 Roche Diagnostics/
Ventana
RTU 
Her2 Rabbit 4B5 Roche Diagnostics/
Ventana
RTU 
Ki-67 Rabbit 30-9 Roche Diagnostics/
Ventana
RTU 
EGFR Rabbit 5B7 Roche Diagnostics/
Ventana
RTU 
CK5/6 Mouse D5 and 16B4 Roche Diagnostics/
Ventana
RTU 
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Statistical analysis
In statistical analyses, TILs were evaluated as continuous 
variables since, in literature, no formal recommendations 
for clinically relevant thresholds TIL have been given this 
far (Salgado et al. 2015). Two categories (present vs absent) 
were used in the analysis of TLSs. Immunoexpressions for 
CD8, CD20 and CD68 were classified into subgroups with 
low vs high inflammatory response based on the median 
value calculated separately for the central and the peripheral 
tissue core of each tumor. Correspondingly, CD163, FoxP3 
and Mac387 clone were analyzed in two categories (negative 
vs positive). IHC for Securin and Separase was categorized 
into subgroups with high vs low immunoexpression apply-
ing thresholds presented in the previous literature (Gurvits 
et al. 2016, 2017).
Clinical parameters, survival rates and each of the stud-
ied inflammatory markers were first analyzed using contin-
gency tables and Fisher’s exact test detecting differences in 
frequencies. Prognostic explorations of the data were per-
formed using Kaplan–Meier estimates to demonstrate the 
cumulative percentages of breast cancer-specific mortal-
ity. Log rank tests and Cox’s regression models were used 
to assess associations between disease outcome, extent of 
inflammatory response and clinical prognostic features, i.e., 
patient’s age at diagnosis, tumor size and axillary lymph 
node status. Each association between the studied proteins 
and the routine prognosticator was quantitated as hazard 
ratio (HR) with 95% confidence interval (CI). p values under 
0.05 were considered significant. Patients with missing data 
were censored from the data. Statistical analyses were per-
formed with R Statistical Software (R Development Core 
Team 2017). The survival analysis package (Therneau and 
Lumley 2019) was used for Cox regression models, while 
Kaplan–Meier plots were drawn using the Survminer pack-
age (Kassambara and Kosinski 2018).
Results
As evaluated from the whole tissue sections, the average 
area fraction of stromal TILs in the TNBCs was 29.1% (SE 
1.8%). Almost one-third (29.9%) of the tumors showed TILs 
in more than 50% of the stromal area and 5.0% in more 
than 90% of the stroma area (Table 3). In 11.7% of tumors 
no stromal TILs were observed. When evaluated from dif-
ferent tumor areas, TIL infiltration was encountered more 
commonly in the invasive front than in the central part of 
the tumors. Also, the average area fraction of stromal TIL 
infiltration was more extensive in the invasive front (32.8%) 
than in the central part (22.9%) of the tumor. The fraction of 
intratumoral TILs in relation to cancer cells was 4.8% (SE 
0.5) as evaluated from the whole tumor area. Intratumoral 
inflammatory reaction in the tumors was sparse so that clear 
expression (> 10%) of intratumoral TILs was observed in 
12.3% of cases while 38.1% of cases showed no intratumoral 
TILs. In our material, the presence of intratumoral TILs was 
associated with higher than average extent of stromal TILs 
(35.3%) while in the absence of intratumoral TILs also the 
extent of stromal TILs was decreased (15.3%). The extent of 
intratumoral TILs did not markedly differ between the cen-
tral area (5.6%) and the invasive front (4.3%) of the tumor. 
Only a single tumor in the material was observed with ter-
tiary lymphoid structures, possibly because the perimeter of 
the tumor was not abundantly represented in the sections. 
The area fraction of stromal TILs was also evaluated in asso-
ciation with features of malignant cell proliferation and CIN 
based on Securin and Separase IHC. In the results, low area 
fraction of stromal TILs was significantly associated with 
high immunoexpressions for Securin (≥ 10% of cancer cells) 
(p = 0.003) and Separase (≥ 1% of cancer cells) (p = 0.01).
Immunohistochemical expressions of CD8, CD20, 
CD68, CD163, FoxP3 and MAC387 clone were evaluated 
from the TMA cores representing the center and the inva-
sive front of the tumors. CD8 immunopositivity was seen 
in almost all TNBCs and equally expressed in TMA cores 
from the central area and invasive front (Table 4). Among 
the  CD8+ tumors, an average of 24.6% (range 0–83.6) of 
TILs was immunopositive as compared to all tumor infil-
trating inflammatory cells. CD20 immunopositivity was 
observed in the central area as well as the invasive front 
in slightly more than half of the tumors and the fraction 
of  CD20+ TILs in the immunopositive tumors was 9.2% 
(range 0–66.5). CD68 was also regularly observed in the 
TNBCs, in the central area as well as in the invasive front. 
The average fraction of  CD68+ TILs in the immunopo-
sitive tumors was 4.8% (range 0–25). As evaluated from 
the central cores, CD163, FoxP3 and MAC387 clone 
Table 3  The fraction (%) of TNBC patients (n = 179) showing stro-
mal and intratumoral TILs as evaluated from the whole tumor area, 
from tumor center and invasive front
The table also shows the fractions of patients with tumors showing 
different extents (> 10%, > 20%, > 50% and > 90%) of stromal and 
intratumoral TIL infiltrations
Stromal TILs (%) Intratu-
moral 
TILs (%)
Whole tumor area 88.3 61.9
TIL > 10% 54.2 87.7
TIL > 20% 44.1 8.9
TIL > 50% 29.9 < 1
TIL > 90% 5.0 0
Tumor center 22.9 49.2
Invasive front 33.8 58.1
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immunopositivity was observed in 53.3%, 45.0% and 
21.2% of the TNBCs, respectively. Evaluating from tissue 
cores representing the invasive front, immunopositivity 
for CD163 and FoxP3 and MAC387 clone was more fre-
quent (71.4%, 51.4% and 38.7% of the TNBCs, respec-
tively). Concerning cancer cell proliferation, low fraction 
of  CD8+ TILs was associated with high immunoexpression 
of Securin (≥ 10% of cancer cells) (p = 0.02) but not with 
Separase-IHC.
Among all studied indicators of inflammatory response, 
the density of TILs and CD8-IHC showed prognostic value 
in TNBC (Table 5). Concerning TILs, the area fraction of 
stromal TILs was associated with breast cancer-specific sur-
vival while the extent of intratumoral TILs or the presence 
of TLS did not predict disease outcome. High fraction of 
stromal TILs in the central area of the tumor—but not in the 
whole tumor area or in the invasive front—was significantly 
associated with favorable outcome of disease. Evaluated as 
a continuous variable, stromal TILs in the central area of 
the tumor predicted 2.4-fold increased probability of dis-
ease survival (p = 0.02). The practical interpretation is that 
each 10% increment in stromal TIL indicated 20% reduced 
risk of death in TNBC. More favorable outcome was also 
observed for TNBCs rich in  CD8+ TILs. Instead, low fre-
quency of CD8-positive inflammatory cells (< 14% of TILs), 
as evaluated from the TMA core representing the periphery 
of the tumor, predicted more than doubled risk of breast 
cancer death (HR 2.1, p = 0.02) (Fig. 1). The frequency of 
 CD8+ TILs evaluated from the TMA core representing the 
tumor center sparsely failed to show statistical significance 
(p = 0.06). In our analyses, no statistically significant prog-
nostic associations were observed for CD20, the studied 
macrophage markers or FoxP3.
Among the studied clinical prognosticators, large tumor 
size (≥ 2 cm in diameter) and postmenopausal status at the 
time of diagnosis showed significantly decreased survival 
in TNBC (Table 5). An even stronger prognostic associa-
tion was observed when comparing the subgroup of post-
menopausal patients with large tumor size with the sub-
group of premenopausal patients with small tumors (HR 
2.9, p = 0.004). Also, the patient subgroups combining 
large tumor size, postmenopausal status or the combination 
of both and low area fraction of stromal TILs were asso-
ciated with up to twofold risk of breast cancer mortality 
(p < 0.005). Correspondingly, patients with large tumors and 
low frequency of  CD8+ TILs were associated with 2.9-fold 
increased risk of cancer mortality as compared to patients 
with small tumor size rich in  CD8+ TILs (p = 0.001). No 
prognostic associations were observed for axillary lymph 
node status or basal differentiation of cancer cells.
In multivariate analyses (Table 5), low area fraction of 
stromal TILs and low frequency of  CD8+ TILs were found 
to be independent prognosticators of survival in TNBC (HR 
2.2, p 0.03 and HR 1.8, p 0.005, respectively), along with 
large tumor size and postmenopausal status.
Table 4  The fraction (%) of TNBC patients (n = 147) showing immu-
nopositivity for CD8, CD20 and CD68 in the TMA cores represent-
ing tumor center and invasive front
The table also shows the fractions of patients with tumors showing 
different extents (> 10%, > 50%, > 90%) of immunopositive TILs
CD8 CD20 CD68
Tumor center
 IHC positive 77.5 60.0 70.6
  > 10% of TILs 54.1 20.2 6.5
  > 20% of TILs 33.3 5.8 0
  > 50% of TILs 8.2 1.7 0
  > 90% of TILs 0 0 0
Invasive front
 IHC positive 78.1 61.2 79.6
  > 10% of TILs 53.5 12.3 4.3
  > 20% of TILs 31.4 3.1 0
  > 50% of TILs 8.8 0 0
  > 90% of TILs 0 0 0
Table 5  Univariate prognostic analyses involving TILs, immuno-
histochemical (IHC) inflammatory markers and established clinical 
prognosticators revealed the prognostic values of stromal TILs, CD8-
IHC, tumor size and the patients’ menopausal status at diagnosis of 
TNBC (n = 147) individually and in combinations. The features with 
independent prognostic value were tested in multivariate analysis. 
The results are expessed as razard ratios (HR) and 95% confidence 
intervals (CI) of breast cancer-spesific mortality. Only assosiations 
with statistical signifigance (p < 0.05) are presented
HR p CI
Univariate analysis
 TIL (as continuous variable) 2.4 0.02 1.2–5.2
 CD8 (< 14% of TILs) 2.1 0.02 1.1–4.5
 Tumor size (≥ 2 cm in diameter) 2.0 0.02 1.2–3.6
 Postmenopausal status 2.2 0.03 1.2–4.2
 TIL and tumor size 1.8 0.003 1.0–2.6
 TIL and postmenopausal status 1.8 0.002 1.1–3.5
 TIL and tumor size and postmeno-
pausal status
2.0 0.005 1.1–3.9
 CD8 and tumor size 2.9 0.004 1.1–3.8
Multivariate analysis model 1
 TIL 2.2 0.03 1.0–3.8
 Tumor size 4.4 0.001 1.2–3.2
 Postmenopausal status 2.9 0.004 1.1–3.0
Multivariate analysis model 2
 CD8 1.8 0.005 1.1–4.4
 Tumor size 2.2 0.001 1.1–3.6
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Discussion
TILs represent a vital component of the local anti-cancer 
immune response. In recent years, TILs have been proposed 
with prognostic value in several malignancies, including 
melanomas and carcinomas of the upper and lower gas-
trointestinal tract (Balatoni et al. 2018; Zheng et al. 2017; 
Galon et al. 2012). In breast cancer, the association of tumor-
infiltrating lymphocytes with disease outcome has been rec-
ognized since decades (Moore and Foote 1949) and has, 
more recently, been verified in a number of large studies 
(Yu et al. 2016; Mao et al. 2016; Savas et al. 2016). Among 
breast carcinomas, TNBC comprises a distinct disease entity 
with a unique microenvironment of TILs and TAMs, and 
high proliferative activity with frequent CIN of the cancer 
cells (Yu and Di 2017; Yang et al. 2018). In our results, low 
area fraction of stromal TILs in the central area of the tumor 
predicted 2.4-fold increased probability of disease survival 
(p = 0.02). The practical interpretation of our results is that 
each 10% decrease in the fraction of stromal TILs results 
in 20% increased risk of mortality in TNBC, correspond-
ing to findings in the previous literature (Loi et al. 2014). 
In multivariate analyses, deficiency of stromal TILs was 
an independent prognosticator of mortality in TNBC (HR 
2.2, p = 0.03). Previously, corresponding conclusions on the 
associations between the frequency of TILs and outcome 
of TNBC have been presented both on the basis of mor-
phological observations as well as expression profiling of 
immunomodulatory genes (Loi et al. 2014; Ibrahim et al. 
2014; Desmedt et al. 2008). In the literature, TILs have even 
been suggested to predict the prognosis of residual disease 
after neoadjuvant treatment (Dieci et al. 2018; Denkert et al. 
2015). In agreement with our results, tissue-assosiated mac-
rophages have not been shown with independent prognostic 
value in TNBC (Mahmoud et al. 2012; Miyasato et al. 2017) 
although they have been suggested to promote proliferative 
activity, tumor growth and disease progression (Santoni 
et al. 2018; Levano et al. 2011).
In previous literature, divergent findings have been pre-
sented on the value of TIL subgroups in predicting the 
outcome of different malignancies. Prognostic associa-
tions have most commonly been observed for  CD8+ cyto-
toxic T cells, but in some malignancies also for  FOXP3+ 
regulatory and  CD4+ helper T cells (de la Cruz-Merino 
et al. 2013). Activated  CD8+ T lymphocytes are critically 
involved in the adaptive immunological defense and are 
known to kill cancer cells by several mechanisms (Mar-
tínez-Lostao et al. 2015). In our results, low frequency of 
 CD8+ inflammatory cells (< 14% of TILs) in the periphery 
of the tumor predicted 2.1-fold increased risk of mortality 
in TNBC (p = 0.02). Concluding from the Kaplan–Meier 
curves (Fig.  1), the majority (75%) of patients with 
decreased fraction of  CD8+ TILs (< 14% of TILs) died 
within an average of 2.2 years after diagnosis whereas 
the majority of patients with high frequency (≥ 14% of 
TILs) were alive in average 15.4 years after diagnosis. 
Fig. 1  Survival of TNBC based on inflammatory response, tumor size 
and menopausal status of the patients (n = 179). a Patients showing 
high (≥ 14%, curve a) vs low fraction (< 14%, curve b) of  CD8+ T 
cells (p = 0.02), b pre- (curve a) vs postmenopausal (curve b) patients 
(p = 0.03), c small (< 2 cm, curve a) vs large (≥ 2 cm, curve b) tumor 
size (p = 0.02), d small tumor size and premenopausal status (curve a) 
vs large tumor size and postmenopausal status (curve d) (p = 0.001). 
The survival of patients with small tumor size and postmenopausal 
status (curve b) does not significantly differ from patients with large 
tumor size and premenopausal status (curve c)
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The observed association between low frequency of  CD8+ 
TILs and unfavorable outcome of TNBC is in line with the 
main part of the literature (Ibrahim et al. 2014; Ali et al. 
2014) although others have reported a reversed associa-
tion between  CD8+ TILs and disease outcome (Matkowski 
et al. 2009) or no prognostic impact at all (Aaltomaa et al. 
1992). High infiltration of  CD8+ TILs has also been sug-
gested to predict response to immune checkpoint blocking 
therapies (Rashidian et al. 2017). We did not detect signifi-
cant prognostic impact for the other studied TIL subpopu-
lations although in some malignancies improved survival 
has been detected in association with increased frequency 
of  FoxP3+ or  CD20+ lymphocytes (Mao et al. 2016).
According to evidence from gene expression profiling, 
immune response and proliferation are interrelated features 
in malignancy (Nagalla et al. 2013; Bianchini et al. 2010). 
CIN and aneuploid DNA content—common features of 
TNBC—have been reported in association with upregulation 
of genes mediating pro-inflammatory signals of the tumor 
microenvironment (Santaguida et al. 2017). On the subcel-
lular level, aneuploidy is most commonly encountered as 
a result of missegregation at the spindle poles caused by 
defects at the metaphase–anaphase transition (Haschka et al. 
2018). Regulation of the metaphase–anaphase transition is 
considered one of the events during the cell cycle where 
the cell is at its most vulnerable and susceptible to genetic 
disorders (Dominguez-Brauer et al. 2015). The transition 
is critically regulated by the APC/C (Anaphase-Promoting 
Complex/or Cyclosome) involving Securin (Pituitary tumor-
transforming gene 1 protein, PTTG1) and Separase (Extra 
spindle poles-like 1 protein, ESPI1) to drive the cell into 
chromosome segregation and anaphase progression (Musac-
chio 2015). In the present observations, immunohistochemi-
cally detected overexpression of Securin and Separase was 
associated with the area fraction of stromal TILs (p = 0.003 
and p = 0.01, respectively) and overexpression of Securin 
with  CD8+ TILs (p = 0.02). Also this finding insinuates that 
uncontrolled proliferation may be linked to inflammatory 
response in TNBC. In the literature, the benefits of immu-
notherapies in TNBC have been partly explained by the high 
mutational levels resulting in a large number of immunoge-
netic neoantigens (Brown et al. 2014). However, the exact 
mechanisms of the interaction between immune response 
and proliferation in cancer have not yet been thoroughly 
explained. However, accumulating data points at inflam-
matory mediators directly or indirectly downregulate DNA 
repair pathways and cell cycle checkpoints, thus destabiliz-
ing cancer cell genome and contributing to the accumulation 
of random genetic alterations (Hanahan and Weinberg 2011; 
Colotta et al. 2009).
In the literature, no univocal principles or clinically rel-
evant guidelines can be found for quantifying the inflam-
matory response in malignancy. According to international 
recommendations for breast cancer (Salgado et al. 2015; 
Hendry et al. 2017; https ://www.tilsi nbrea stcan cer.org), we 
used full tumor sections to assess the area fractions of TILs 
while immunohistochemical identification of TIL subtypes 
was performed in TMA cores specifically chosen to rep-
resent tumor inflammation. Biopsy material was excluded 
from the study. The evaluations were performed in digitized 
images and, when applicable, using an image analysis soft-
ware to standardize the quantifications. In the literature, con-
tradictory perceptions reign on the impact of the localization 
of inflammation on the outcome of different malignancies, 
including TNBC (Li et al. 2019; Liu et al. 2012; Ali et al. 
2014; Angell and Galon 2013; Galon et al. 2016). Based on 
our findings from different tumor compartments, the highest 
prognostic significances were observed for the area fraction 
of TILs in the center and the fraction of  CD8+ TILs at the 
invasive front of the tumor. Previous literature also lacks 
systematic cutpoints applicable to classifying inflammatory 
response in malignancy. In agreement with the previous lit-
erature (Salgado et al. 2015), our analyses did not provide a 
single statistically significant cutpoint for the area fraction 
of TILs and, therefore, TIL was involved in the prognostic 
analyses as a continuous parameter. However, in statisti-
cal analyses supported by morphological observations, we 
were able to identify for  CD8+ TILs a cutpoint which opti-
mally distinguished patients alive vs dead of TNBC (≥ 14% 
vs < 14%  CD8+ TILs, respectively). Obviously, this classifi-
cation is not directly applicable to other patient materials or 
institutions. Taken together, the several sources of variation 
remain a challenge for the application of immune markers 
in routine clinical practice for patients suffering from TNBC 
(Denkert et al. 2016).
TNBC comprises 10–20% of all breast carcinomas and 
is characterized by aggressive behavior, young age at diag-
nosis and high risk of relapse and mortality. In addition, 
the challenges of TNBCs include lack of specific prognostic 
features and targeted therapies. Previous literature and the 
present results show that—despite being an established com-
ponent of breast cancer staging—axillary lymph node status 
is not an independent prognostic feature in TNBC (Gangi 
et al. 2014). Instead, based on our material of a total of 179 
patients with complete clinical data and up to 18-year fol-
low-up, the area fraction of TILs and the frequency of  CD8+ 
TILs comprised promising markers for survival in TNBC. 
The prognostic impact of these features of inflammatory 
response was also evident when combined with tumor size 
and postmenopausal status. Applications of inflammatory 
response in patient treatment may benefit from systematic 
principles and clinically relevant guidelines for evaluation. 
The results suggest that in future significant improvements 
in prognostication and treatment of TNBC may be reached 
by increased understanding of the cellular composition and 
interactions of the inflammatory tumor microenvironment.
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